Blackstone Life Sciences
North America, Massachusetts, United States, Cambridge
Description
Blackstone Life Sciences is a private equity segment of The Blackstone Group.
Investor Profile
Blackstone Life Sciences has backed more than 17 startups, with 2 new investments in the last 12 months alone. The firm has led 10 rounds, about 59% of its total and boasts 13 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Post Ipo Equity, Series C, Series B rounds (top funding stages).
- Majority of deals are located in United States, France.
- Strong thematic focus on Biotechnology, Health Care, Therapeutics.
- Led 1 rounds in the past year.
Stage Focus
- Post Ipo Equity (47%)
- Series C (18%)
- Series B (12%)
- Series A (12%)
- Post Ipo Debt (6%)
- Series D (6%)
Country Focus
- United States (94%)
- France (6%)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
- Medical
- Pharmaceutical
- Biopharma
- Life Science
- Precision Medicine
- Health Diagnostics
- Alternative Medicine
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
